000 05658cam a2200481Mi 4500
988 _aSpringer_Medicine_2017
999 _c96409
_d96409
_x1
001 96409
003 ES-MaUEC
005 20230102112752.0
006 m o d
007 cr cnu---unuuu
008 170812s2017 xx o 000 0 eng d
020 _a3319504827
_q(electronic bk.)
020 _a9783319504827
_q(electronic bk.)
020 _z3319504800
020 _z9783319504803
040 _aEBLCP
_cEBLCP
_dN$T
_dYDX
_dGW5XE
_dOCLCF
_dUAB
_dAZU
_dOCLCQ
_dUPM
_dMERER
_dOCLCQ
_dESU
_dIOG
_dOCL
_dCOO
_dOCLCO
_dOCL
_dES-MaUEC
_bspa
050 4 _aRA410
_b2017 EB
100 1 _aMauskopf, Josephine.
245 1 0 _aBudget-Impact Analysis of Health Care Interventions :
_ba Practical Guide.
264 1 _aCham
_bSpringer International Publishing
_c2017.
300 _a1 recurso en línea (234 páginas)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
500 _a6.2.1 Acute Conditions or Chronic Conditions Where Changes Occur Almost Immediately.
500 _aSpringerLink
505 0 _aAuthor Contributions; Foreword; Preface; Abbreviations; Contents; Chapter 1: Introduction to Budget-Impact Analysis; 1.1 What Is Budget-Impact Analysis?; 1.2 Budget-Impact Analyses Compared with Cost-ƯEffectiveness Analyses; 1.3 Uses of Budget-Impact Analyses; 1.4 Guidelines for Budget-Impact Analyses; 1.5 Overview of Chapters in This Book; Exercises; References; Chapter 2: Determining the Analytic Framework; 2.1 Eligible Population in Jurisdiction; 2.1.1 Impact of Positioning of the New Drug Within the Current Treatment Pathway on Eligible Population Size.
505 8 _a2.1.2 Impact of Regulatory Approval on Eligible Population Size2.1.3 Impact of Reimbursement Decisions on Eligible Population Size; 2.1.4 Impact of New Drug Attributes on Initial Population Size; 2.1.5 Impact of New Drug Attributes on Population Size Over Model Time Horizon; 2.2 Budget Holder Time Horizon; 2.3 Potential Use of the New Drug Within the Treatment Mix; 2.4 Budget Holder Cost Perspective; 2.4.1 Service Delivery Cost Versus Reimbursement Rate; 2.4.2 Fixed Versus Variable Costs; 2.4.3 Cost Categories of Interest; 2.5 Compilation of Analytic Framework; Exercises; References.
505 8 _a3.7 Which Eligible Population Should We Include in the Budget-Impact Analysis?Exercises; References; Chapter 4: Estimating the Treatment Mix; 4.1 Treatment Shares Without the New Drug in the Treatment Mix; 4.2 Treatment Shares with the New Drug in the Treatment Mix; 4.3 Which Treatment Shares Should We Include in the Budget-Impact Analysis?; Exercises; Reference; Chapter 5: Estimating Treatment-Related Costs; 5.1 Costs for Drug Acquisition; 5.1.1 Co-payments and Coinsurance; 5.1.2 Dispensing Fees; 5.1.3 Dose Levels; 5.1.4 Duration of Treatment; 5.2 Costs for Administering the Drug.
505 8 _a5.3 Costs for Diagnostic Tests to Determine Eligibility for the Drug5.4 Costs for Monitoring the Drug for Safety and Efficacy; 5.5 Costs for Treating Side Effects Associated with the Drug; 5.6 Accounting for Differing Treatment Costs in the First and Subsequent Treatment Years; 5.7 Accounting for Other Treatment Costs; 5.8 Estimating Resource Use Changes with the New Drug; Exercises; References; Chapter 6: Estimating Condition-Related Costs; 6.1 Why the New Drug Might Change Condition-Related Costs; 6.2 Estimating Changes in Condition-Related Costs for Incident Populations.
505 8 _aChapter 3: Estimating the Diagnosed, Treated, and Eligible Population3.1 Incident and Prevalent Populations; 3.2 Estimating the Eligible Population Size; 3.3 Data for Identifying the Eligible Population; 3.4 Estimating Population Size by Subgroup; 3.5 Changing Size of the Eligible Population Over the Analysis Time Horizon; 3.5.1 Changing Population Size Regardless of Introduction of the New Drug; 3.5.2 Changing Population Size and Condition Severity Mix due to the Introduction of the New Drug; 3.6 Including Catch-Up Effects for the Prevalent Population.
520 3 _aThe first of its kind for budget-impact analysis, this comprehensive guide provides clear and concise instructions for evaluating the impact that new pharmaceuticals will have on the budget for a specific jurisdiction. The book demonstrates how to create a budget-impact analysis using a simple six-step process that is consistent with current guidelines for these analyses. Examples and exercises for each chapter afford an opportunity to practice the six-step process in practical applications. The book progresses from a framework for budget impact analyses to an in-depth review of components and how to develop and present these in software applications and reports. Critical considerations such as uncertainty analysis and validation, and considerations for alternate interventions, such as vaccines and diagnostics, are also covered. This book is a "must have" for the builder and budget holder, with builders benefiting from instructions to identify and estimate all necessary variables and budget holders receiving a guide to what should be included in the analyses they assess.
650 7 _aEconomía de la salud
_2embne
_9150344
700 1 _aBrodtkorb, Thor-Henrik.
700 1 _aBrogan, Anita.
700 1 _aEarnshaw, Stephanie R.
700 1 _aWolowacz, Sorrel.
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-50482-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI